好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebral Visual Impairment in Cerebral Adrenoleukodystrophy: Prevalence, Presentation, and Neuroimaging Correlates
Child Neurology and Developmental Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
6-004

To assess the prevalence, presentation, and neuroimaging correlates of cerebral visual impairment (CVI) and visual processing deficits associated with cerebral adrenoleukodystrophy (CALD).

X-linked adrenoleukodystrophy is a single gene disorder characterized by defective β-oxidation of very long chain fatty acids. Without treatment, the cerebral demyelinating phenotype, CALD, causes rapid neurologic decline, ultimately progressing to total neurologic disability within months to three years of symptom onset. With the advent of newborn screening and both allogeneic and experimental autologous stem cell transplantation, it is now possible to halt the progression of CALD at increasingly earlier timepoints in the natural history of the disease. Higher order visual processing deficits are a particularly relevant focus of study as they may serve as an early marker of neurologic decline and potentially identify an earlier window of opportunity for treatment.

Medical records were retrospectively reviewed for all male CALD patients seen at Massachusetts General Hospital between June 2005 and July 2020 (n=89). Neurological assessments and neuropsychological tests were reviewed to assess for signs and symptoms of CVI. Brain MRIs were reviewed to evaluate lesion burden.

Forty-nine percent of patients had findings suggestive of CVI, most commonly a deficit/decline in visual perceptual reasoning as assessed by formal neuropsychological testing (32%), a visual field cut (29%), or a deficit/decline in visual-motor integration (29%). Symptoms were not limited to a single pattern of lesion progression (e.g. posterior-predominant vs. anterior-predominant). Symptoms were prevalent in 31% of patients with very early lesions (Loes score ≤3). Symptoms presented as late as two years following hematopoietic stem cell transplantation (HSCT).

CVI is prevalent not just among untreated, advanced symptomatic CALD patients, but also in those with very early lesions who have undergone successful HSCT. Even patients considered ideal transplant candidates based on Loes score and overall clinical picture may not experience functionally optimal outcomes.

Authors/Disclosures
Melissa Bambery, Other (Massachusetts General Hospital)
PRESENTER
Ms. Bambery has nothing to disclose.
Camille S. Corre, MD (University of Rochester Medical Center) Dr. Corre has nothing to disclose.
Amanda M. Nagy, MD (Massachusetts General Hospital) Dr. Nagy has nothing to disclose.
No disclosure on file
No disclosure on file
Daniel C. Kelly Mr. Kelly has nothing to disclose.
No disclosure on file
Florian Eichler, MD (Massachusetts General Hospital) An immediate family member of Dr. Eichler has received personal compensation for serving as an employee of UpToDate. Dr. Eichler has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for SwanBio Therapeutics. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Eichler has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Leal Therapeutics. Dr. Eichler has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Swan Bio. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. Dr. Eichler has stock in SwanBio Therapeutics. The institution of Dr. Eichler has received research support from Minoryx Therpeutics. The institution of Dr. Eichler has received research support from ASPA Therapeutics. The institution of Dr. Eichler has received research support from bluebird bio. The institution of Dr. Eichler has received research support from Ionis Pharmaceuticals. Dr. Eichler has received intellectual property interests from a discovery or technology relating to health care.